GlaxoSmithKline's global media business looks set to remain in the hands of incumbents PHD and GroupM's MediaCom and other agencies. However, a reallocation of duties is likely. Currently PHD manages

GlaxoSmithKline is joining forces with tech developer Verily - a unit of Google parent Alphabet Inc - to develop "bioelectronic" medicines to combat diseases such as arthritis, diabetes and asthma. This

deal at Unilever is expected to be the acquisition of GlaxoSmithKline's nutritional portfolio, led by the malt beverage Horlicks, a mammoth brand in India worth around $3bn. An announcement is expected

unusual addition to the coffee machine sector comes from GlaxoSmithKline, which this week launched a line of "PowerPods" for its Theraflu cold and flu remedy in the US. The single-serve capsules are designed

First up was GlaxoSmithKline's global media. GroupM handled most of the account worldwide, split between Mediacom, Mindshare and Essence. Omnicom's PHD had the US, Australia and New Zealand. However,

Another week, another big media review. GlaxoSmithKline is the latest global giant to reconsider media buying and planning arrangements. It piles yet more pressure onto WPP, whose Mediacom has most of

withdrew mid-week, leaving rival GlaxoSmithKline with a clear path to conclude a deal. However, the British group also dropped its bid on Friday. Both companies indicated the high cost of the business

Meanwhile, former GlaxoSmithKline CEO Andrew Witty is the surprise choice to lead UnitedHealth Group's pharmacy benefits division Optum, which negotiates drug prices on behalf of insurers and employers.

GlaxoSmithKline and Reckitt Benckiser. Most observers expect RB to win the prize, since GSK would need the approval of its healthcare partner Novartis, which might not be forthcoming. Meanwhile, the simultaneous

trading standards regulator turned its attention to GlaxoSmithKline and Novartis. The Australian Competition & Consumer Commission began proceedings against their GSK Consumer Healthcare joint venture